Evidence map›Paper›PMID 35290115›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2022

A system for multiplexed selection of aptamers with exquisite specificity without counterselection.

Alex M Yoshikawa, Leighton Wan, Liwei Zheng, Michael Eisenstein, H Tom Soh

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Advances in aptamer technology for target-based drug discovery.Journal of pharmaceutical analysis · 2026
    Review
  5. Review
  6. Article
  7. Dissociation Constant (KSmall methods · 2025
    Review
  8. Continuous Molecular Monitoring for Precision Heart Failure Care.JACC. Basic to translational science · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alex M YoshikawaDepartment of Chemical Engineering, Stanford University, Stanford, CA 94305.
Leighton WanDepartment of Bioengineering, Stanford University, Stanford, CA 94305.ORCID 0000-0001-8935-4144
Liwei ZhengDepartment of Radiology, Stanford University, Stanford, CA 94305.
Michael EisensteinDepartment of Radiology, Stanford University, Stanford, CA 94305.
H Tom SohDepartment of Radiology, Stanford University, Stanford, CA 94305.ORCID 0000-0001-9443-857X

Funding

Real-time biosensor for mapping the function of the pancreasOT2OD025342 · OD · STANFORD UNIVERSITY · PI SOH, HYONGSOK TOM · 2018 to 2021
$4.6M
NIH HHS OT2 OD025342Office of Extramural Research, National Institutes of Health (OER) R01GM129314-01
6 · The paper itself

Abstract

Aptamers have proven to be valuable tools for the detection of small molecules due to their remarkable ability to specifically discriminate between structurally similar molecules. Most aptamer selection efforts have relied on counterselection to eliminate aptamers that exhibit unwanted cross-reactivity to interferents or structurally similar relatives to the target of interest. However, because the affinity and specificity characteristics of an aptamer library are fundamentally unknowable a priori, it is not possible to determine the optimal counterselection parameters. As a result, counterselection experiments require trial-and-error approaches that are inherently inefficient and may not result in aptamers with the best combination of affinity and specificity. In this work, we describe a high-throughput screening process for generating high-specificity aptamers to multiple targets in parallel while also eliminating the need for counterselection. We employ a platform based on a modified benchtop sequencer to conduct a massively parallel aptamer screening process that enables the selection of highly specific aptamers against multiple structurally similar molecules in a single experiment, without any counterselection. As a demonstration, we have selected aptamers with high affinity and exquisite specificity for three structurally similar kynurenine metabolites that differ by a single hydroxyl group in a single selection experiment. This process can easily be adapted to other small-molecule analytes and should greatly accelerate the development of aptamer reagents that achieve exquisite specificity for their target analytes.

Indexed as

Aptamers, NucleotideSELEX Aptamer TechniqueHigh-Throughput Screening AssaysAptamers, Nucleotideaffinity reagentaptamercounterselectionSELEX

Identifiers

PMID35290115
PMCPMC8944265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.